18F-FDG PET-CT显像与骨髓活检在儿童霍奇金淋巴瘤中的比较:骨髓摄取定量评估及骨髓受累临床意义的新见解
该回顾性研究纳入2010年7月至2015年6月间784例儿童霍奇金淋巴瘤患者,以骨髓活检为参考标准,评估18F-FDG PET-CT预测骨髓受累的准确性。PET检测骨髓受累的灵敏度93.6%、特异度94%、阳性预测值53%、阴性预测值99.4%,较骨髓活检更敏感。作者认为骨髓活检应限于骨髓摄取正常但存在不良危险因素者,或弥漫性摄取增高者以排除反应性骨髓背景下的骨髓受累。
要点
- 784例患儿中104例(13.3%)存在骨髓受累,PET检出100例,骨髓活检检出58例。
- PET与骨髓活检结果一致728例(93%),不一致56例。
- PET检测骨髓受累灵敏度93.6%、特异度94%、阳性预测值53%、阴性预测值99.4%。
核心结论
- 18F-FDG PET-CT显像在儿童霍奇金淋巴瘤分期中检测骨髓受累较骨髓活检更敏感。
- 作者认为骨髓活检应限于骨髓摄取正常但存在不良危险因素者,或弥漫性摄取增高者以排除反应性骨髓背景下的骨髓受累。
研究设计与样本
- 回顾性分析2010年7月至2015年6月间所有接受分期18F-FDG PET-CT扫描和骨髓活检的儿童霍奇金淋巴瘤病例,参考标准为骨髓活检。
- 共纳入784例患者,其中男性83.3%、女性16.7%,年龄2至18岁(平均10.3岁)。
- 将IV期患者分为PET+ BMB-、PET+ BMB+和PET- BMB-三组,比较无进展生存和总生存。
主要发现
- 784例中104例(13.3%)存在骨髓受累,其中PET检出100例,骨髓活检检出58例。
- PET与骨髓活检在728例(93%)中结果一致:阳性一致54例,阴性一致674例。
- 56例不一致病例中,4例PET假阴性并被骨髓活检升级分期,46例局灶摄取者为PET/CT阳性而骨髓活检阴性(未从活动部位获取),6例弥漫摄取者为PET假阳性,归因于副肿瘤性骨髓激活。
- PET识别骨髓受累的灵敏度93.6%、特异度94%、阳性预测值53%、阴性预测值99.4%。
- 定量评估显示,存在骨髓受累者双侧髂嵴平均iBM-SUVmax显著高于无骨髓受累者(p < 0.05)。
关键数值与推荐
- PET检测骨髓受累的灵敏度93.6%、特异度94%、阳性预测值53%、阴性预测值99.4%。
- 存在骨髓受累者双侧髂嵴平均iBM-SUVmax显著高于无骨髓受累者(p < 0.05)。
临床怎么用
- 作者认为骨髓活检应限于骨髓摄取正常但存在不良危险因素者,或弥漫性摄取增高者以排除反应性骨髓背景下的骨髓受累。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether positron emission tomography/computed tomography using fluorine-18 fluoro-deoxyglucose (18F-FDG PET-CT) predicts bone marrow involvement (BMI) in pediatric Hodgkin's lymphoma (pHL) with sufficient accuracy to supplant routine staging bone marrow biopsy (BMB), and to assess the clinical importance of marrow disease by comparing the prognosis of stage IV HL with BMI versus that without BMI. METHODS: Data were retrospectively analyzed for all cases of pHL between July 2010 and June 2015 referred for staging 18F-FDG PET-CT scan and BMB. The reference standard was BMB. Stage IV patients were divided into three groups to compare their progression-free and overall survival: PET+ BMB-, PET+ BMB+, and PET- BMB-. RESULTS: Of the 784 patients, 83.3% were male and 16.7% female, with age ranging from 2 to 18 years (mean 10.3 years). Among the total cases, 104 (13.3%) had BMI; of these, 100 were detected by PET imaging and 58 by BMB. BMB and 18F-FDG PET/CT scans were concordant for BMI detection in 728 patients (93%): positive concordance in 54 and negative in 674. Of the 56 discordant cases, four had a false-negative PET scans and were upstaged by BMB, 46 with focal uptake were PET/CT-positive and BMB-negative (not obtained from active sites), and six with diffuse uptake were false-positive on PET due to paraneoplastic marrow activation. The sensitivity, specificity, PPV, and NPV of PET for identifying BMI was 93.6, 94, 53, and 99.4% respectively. On quantitative assessment, mean iBM-SUVmax of bilateral iliac crests was significantly higher in those with BMI versus those without (p < 0.05). CONCLUSIONS: 18F-FDG PET-CT imaging is more sensitive than BMB for BMI detection in pHL staging. BMB should be limited to those with normal marrow uptake in the presence of poor risk factors or those with diffusely increased uptake to exclude marrow involvement in the background of reactive marrow.
引用
- Hassan A, Siddique M, Bashir H, et al. 18F-FDG PET-CT imaging versus bone marrow biopsy in pediatric Hodgkin's lymphoma: a quantitative assessment of marrow uptake and novel insights into clinical implications of marrow involvement. Eur J Nucl Med Mol Imaging. 2017. PMID: 28229191. doi:10.1007/s00259-017-3647-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。